{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:58Z","timestamp":1793666758238,"version":"4.5.1"},"reference-count":163,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite the advancements in targeted biologic therapy for immune-mediated inflammatory diseases (IMIDs), significant challenges persist, including challenges in drug maintenance, primary and secondary non-responses, and adverse effects. Recent data have strengthened the evidence supporting stem cell therapy as an experimental salvage therapy into a standard treatment option. Recent preclinical and clinical studies suggested that chimeric antigen receptor T cell (CAR-T) therapy, which depleting tissue and bone marrow B cells, may lead to improvement, even inducing long-lasting remissions for patients with IMIDs. In this review, we address the unmet needs of targeted biologic therapy, delineate the critical differences between stem cell transplantation and CAR-T therapy, evaluate the current status of CAR-T therapy for IMIDs and explore its potential and existing limitations.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1520063","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:18:00Z","timestamp":1744003080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhenguo","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102193","article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019","volume":"64","author":"Collaborators","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01577-7","article-title":"Dynamic regulatory elements in single-cell multimodal data implicate key immune cell states enriched for autoimmune disease heritability","volume":"55","author":"Gupta","year":"2023","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070119-115617","article-title":"Hematopoietic stem cell transplantation for autoimmune disease","volume":"72","author":"Alexander","year":"2021","journal-title":"Annu Rev Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01010-7","article-title":"Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells","volume":"19","author":"Bertolino","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216040","article-title":"Mesenchymal stem cells in the pathogenesis and therapy of autoimmune and autoinflammatory diseases","volume":"24","author":"Zaripova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR t cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR t-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015789","article-title":"CAR t cells as a second-line therapy for large b-cell lymphoma: a paradigm shift","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large b-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large b-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103331","article-title":"Efficacy and safety of advanced combination treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Solitano","year":"2024","journal-title":"J Autoimmun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01036-x","article-title":"25 years of biologic DMARDs in rheumatology","volume":"19","author":"Feldmann","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.023","article-title":"Efficacy of janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement","volume":"76","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.05.009","article-title":"Prediction of response to targeted treatment in rheumatoid arthritis","volume":"92","author":"Wijbrandts","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker300","article-title":"A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm","volume":"51","author":"Tak","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"R160","DOI":"10.1186\/ar4675","article-title":"Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation","volume":"16","author":"Paramarta","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-Severe psoriasis: Focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","article-title":"Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data","volume":"15","author":"Quartuccio","year":"2019","journal-title":"J Adv Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of b cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645478","article-title":"Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE","volume":"12","author":"Humbel","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: A double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: Results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.coi.2019.09.005","article-title":"Pathogenic memory plasma cells in autoimmunity","volume":"61","author":"Chang","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0445-4","article-title":"Homeostasis and regulation of autoreactive b cells","volume":"17","author":"Lee","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224916","article-title":"Unmet need in rheumatology: reports from the advances in targeted therapies meeting, 2023","volume":"83","author":"Winthrop","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13287-025-04184-x","article-title":"Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Zeng","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13287-019-1165-5","article-title":"Stem cells: past, present, and future","volume":"10","author":"Zakrzewski","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.42081","article-title":"Safety and efficacy of mesenchymal stromal cells and other cellular therapeutics in rheumatic diseases in 2022: A review of what we know so far","volume":"74","author":"Gilkeson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.05.020","article-title":"Hematopoietic stem cell transplantation in autoimmune disorders: From immune-regulatory processes to clinical implications","volume":"16","author":"Zeher","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2018.06.002","article-title":"Hematopoietic stem cell therapy for autoimmune diseases - clinical experience and mechanisms","volume":"92","author":"Alexander","year":"2018","journal-title":"J Autoimmun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-018-0627-y","article-title":"Mesenchymal stem cells and immune disorders: from basic science to clinical transition","volume":"13","author":"Wang","year":"2019","journal-title":"Front Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01084-x","article-title":"The therapeutic potential of immunoengineering for systemic autoimmunity","volume":"20","author":"McBride","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41584-023-01073-6","article-title":"The rise of precision cellular therapies","volume":"20","author":"Konig","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR t-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.03.006","article-title":"Therapeutic intersections: Expanding benefits of CD19 CAR t cells from cancer to autoimmunity","volume":"31","author":"Sosnoski","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor t cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.07.056","article-title":"Off-the-shelf CAR-t cells could prove paradigm shifting for autoimmune diseases","volume":"187","author":"Baker","year":"2024","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01126-1","article-title":"CAR t-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR t cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/procel\/pwad061","article-title":"The expanded application of CAR-t cell therapy for the treatment of multiple non-tumoral diseases","volume":"15","author":"Liu","year":"2024","journal-title":"Protein Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.Bcd-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR t therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discovery"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018330","article-title":"Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden","volume":"141","author":"Biondi","year":"2023","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jtct.2024.03.023","article-title":"Fully human anti-CD19 CAR t cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production","volume":"30","author":"Dingfelder","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR t cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1298598","article-title":"Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR t-cells over time","volume":"15","author":"Odak","year":"2024","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-t cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-t cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40779-023-00486-4","article-title":"Insights gained from single-cell analysis of chimeric antigen receptor t-cell immunotherapy in cancer","volume":"10","author":"Tang","year":"2023","journal-title":"Mil Med Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.028","article-title":"Single-cell transcriptomic analysis reveals BCMA CAR-t cell dynamics in a patient with refractory primary plasma cell leukemia","volume":"29","author":"Li","year":"2021","journal-title":"Mol Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR t cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","article-title":"Immunological effects of CD19. CAR-t cell therapy in systemic sclerosis: an extended case study","volume":"26","author":"Claus","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained b cell depletion by CD19-targeted CAR t cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-t cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-t cell targeting three receptors on autoreactive b cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J Autoimmun"},{"key":"B66","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR t cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered t regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab093","article-title":"Formation and immunomodulatory function of meningeal b cell aggregates in progressive CNS autoimmunity","volume":"144","author":"Mitsdoerffer","year":"2021","journal-title":"Brain"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e200080","DOI":"10.1212\/nxi.0000000000200080","article-title":"CAR-t cell-mediated b-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.243","article-title":"Preclinical models in chimeric antigen receptor-engineered t-cell therapy","volume":"29","author":"Siegler","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor t cells deplete NMDA receptor-specific b cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR-t cells and CAR-tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41467-024-46654-5","article-title":"Targeting pathogenic CD8(+) tissue-resident t cells with chimeric antigen receptor therapy in murine autoimmune cholangitis","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110873","article-title":"TSHR-based chimeric antigen receptor t cell specifically deplete auto-reactive b lymphocytes for treatment of autoimmune thyroid disease","volume":"124","author":"Duan","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.12.007","article-title":"Adoptive transfer of mRNA-transfected t cells redirected against diabetogenic CD8 t cells can prevent diabetes","volume":"25","author":"Fishman","year":"2017","journal-title":"Mol Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012495117","article-title":"A biomimetic five-module chimeric antigen receptor ((5M)CAR) designed to target and eliminate antigen-specific t cells","volume":"117","author":"Kobayashi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104224","article-title":"Towards antigen-specific tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor","volume":"358","author":"Radichev","year":"2020","journal-title":"Cell Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) t cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory t cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/jci168601","article-title":"Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018018556","article-title":"Engineered FVIII-expressing cytotoxic t cells target and kill FVIII-specific b cells in vitro and in vivo","volume":"2","author":"Parvathaneni","year":"2018","journal-title":"Blood Adv"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric antigen receptor-redirected regulatory t cells suppress experimental allergic airway inflammation, a model of asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02231","article-title":"Chimeric antigen receptors based on low affinity mutants of FcepsilonRI re-direct t cell specificity to cells expressing membrane IgE","volume":"9","author":"Ward","year":"2018","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01834-9","article-title":"A single infusion of engineered long-lived and multifunctional t cells confers durable remission of asthma in mice","volume":"25","author":"Jin","year":"2024","journal-title":"Nat Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered t cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR t cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific b cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor t cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03328.x","article-title":"Development of chimeric molecules for recognition and targeting of antigen-specific b cells in pemphigus vulgaris","volume":"142","author":"Proby","year":"2000","journal-title":"Br J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor t cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/art.42677","article-title":"Effects of b cell depletion by CD19-targeted chimeric antigen receptor t cells in a murine model of systemic sclerosis","volume":"76","author":"Avouac","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801414105","article-title":"Development of pulmonary fibrosis through a pathway involving the transcription factor fra-2\/AP-1","volume":"105","author":"Eferl","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113779","article-title":"Efficacy and safety of anti-CD19 CAR-t in a mouse model of IgG4-related disease","volume":"145","author":"Sun","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory t cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02084-3","article-title":"Two for one? CAR-t therapy for lymphoma benefits concurrent autoimmune disorders","volume":"58","author":"Bachanova","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16266","article-title":"Chimeric antigen receptor t-cell therapy's role in antiphospholipid syndrome: a case report","volume":"188","author":"Schmelz","year":"2020","journal-title":"Br J Haematol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02086-1","article-title":"CD19-targeted chimeric antigen receptor t-cell therapy in patients with concurrent b-cell non-hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study","volume":"58","author":"Wang","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR t cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","article-title":"Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy","volume":"31","author":"Nunez","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11614","article-title":"Journal club: Anti-CD19 chimeric antigen receptor t cell therapy for refractory systemic lupus erythematosus","volume":"5","author":"Boulougoura","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2403743","article-title":"Anti-CD19 CAR t cells in refractory immune thrombocytopenia of SLE","volume":"391","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"B103","article-title":"An open-label, multicenter, phase 1\/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-t cell therapy targeting CD19 on b cells, for severe refractory systemic lupus erythematosus: Preliminary results [abstract]","volume":"75","author":"Cort\u00e9s Hern\u00e1ndez J","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.1768","article-title":"POS0046.Preliminary results of an open-label, multicentre, phase 1\/2 study to assess safety, efficacy and cellular kinetics of Ytb323 (Rapcabtagene autoleucel), a rapidly manufactured CAR t-cell therapy targeting CD19 on b cells, for severe refractory systemic lupus erythematosus","volume":"83","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00424-0","article-title":"CAR t-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-el.155","article-title":"P101 anti-CD19 CAR-t cell therapy for refractory childhood-onset systemic lupus erythematosus","volume":"11","author":"Emiliano","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR t-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR t cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02265-7","article-title":"Treatment of CNS systemic lupus erythematosus with CD19 CAR t cells","volume":"404","author":"Hagen","year":"2024","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1002\/cti2.1139","article-title":"Plasmacytoid dendritic cell biology and its role in immune-mediated diseases","volume":"9","author":"Ye","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad105","article-title":"Production of functional plasmacytoid dendritic cells - targeted chimeric antigen receptor t cells from patients with immune-mediated inflammatory diseases","volume":"189","author":"Cael","year":"2023","journal-title":"Br J Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor t-cell therapy of b-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J Thromb Haemost"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00023-5","article-title":"CD19-targeted CAR t cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR t cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-t cells after failure of several b-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR t cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR t therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-t therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR t cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-t cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2403705","article-title":"CAR t-cell therapy in autoimmune disease","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"Reply. N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00282-0","article-title":"CD19-targeting CAR t-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive b cells from rheumatoid arthritis patients by universal chimeric antigen receptor t cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR t cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf077","article-title":"Targeting autoimmunity with CD19-CAR t cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis","author":"Albach","year":"","journal-title":"Rheumatol (Oxford)"},{"key":"B128","doi-asserted-by":"publisher","first-page":"keae714","DOI":"10.1093\/rheumatology\/keae714","article-title":"Remission of lymphoma & rheumatoid arthritis following anti-CD19 chimeric antigen receptor t cell therapy for diffuse large b-cell lymphoma","author":"Masihuddin","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-t cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor t-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific b cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B132","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor t cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00470-5","article-title":"CAR-t therapy for multiple sclerosis enters US trials for first time","author":"Mullard","year":"2024","journal-title":"Nature"},{"key":"B134","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR t-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor t-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00375-7","article-title":"Anti-CD19 CAR t cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and lambert-eaton myasthenic syndrome with autologous CD19-targeted CAR t cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e2403227121","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR t cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR t cell therapy induces antibody seroconversion and complete b cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa320","article-title":"Colitis after CAR t-cell therapy for refractory large b-cell lymphoma responds to anti-integrin therapy","volume":"27","author":"Hashim","year":"2021","journal-title":"Inflammation Bowel Dis"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1149450","article-title":"Case report: IBD-like colitis following CAR t cell therapy for diffuse large b cell lymphoma","volume":"13","author":"Zundler","year":"2023","journal-title":"Front Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000","article-title":"How i prevent infections in patients receiving CD19-targeted chimeric antigen receptor t cells for b-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor t-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.37201\/req\/s01.12.2023","article-title":"Post-CART-T cell infection: Etiology, pathogenesis, and therapeutic approaches","volume":"36","author":"Garc\u00eda-Pout\u00f3n","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.021","article-title":"Association of CD19(+)-targeted chimeric antigen receptor (CAR) t-cell therapy with hypogammaglobulinemia, infection, and mortality","volume":"155","author":"Sutherland","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-t cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00402-8","article-title":"Safety of CAR t-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study","author":"Vanni","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR t\u2009cell therapy in the DESCAR-t registry","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"key":"B149","article-title":"Novel BCMA-CD19 compound CAR-t (cCAR) targets b cells and plasma cells achieving immune reset and eliminates all autoantibodies in systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients resulting in long-term, medication-free remission [abstract]","volume":"75","author":"Yuan Y","year":"2023","journal-title":". Arthritis Rheumatol"},{"key":"B150","unstructured":""},{"key":"B151","unstructured":"Artiva biotherapeutics receives FDA fast track designation for AlloNK\u00ae in lupus nephritis"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.2343","article-title":"POS0462.Preclinical development of KYV-201, an investigational allogeneic anti-CD19 CAR-t cell for the treatment of autoimmune disease","volume":"83","author":"Mahne","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B153","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","article-title":"Treatment of adult ALL patients with third-generation CD19-directed CAR t cells: results of a pivotal trial","volume":"16","author":"Schubert","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.002","article-title":"Mechanisms of resistance to CAR t cell therapies","volume":"65","author":"Singh","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100375","article-title":"Non-viral chimeric antigen receptor (CAR) t cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immunooncol Technol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2024.108350","article-title":"Expanding the horizon of transient CAR t therapeutics using virus-free technology","volume":"72","author":"Enriquez-Rodriguez","year":"2024","journal-title":"Biotechnol Adv"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01007-2","article-title":"Inflammation across tissues: can shared cell biology help design smarter trials","volume":"19","author":"Hosack","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41551-022-00969-0","article-title":"Optimization of the proliferation and persistency of CAR t cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat BioMed Eng"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.12.017","article-title":"Dexamethasone potentiates chimeric antigen receptor t cell persistence and function by enhancing IL-7Ralpha expression","volume":"32","author":"Munoz","year":"2024","journal-title":"Mol Ther"},{"key":"B160","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-t cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"B161","doi-asserted-by":"publisher","first-page":"221(2)","DOI":"10.1084\/jem.20230903","article-title":"CAR-t cell manufacturing: Major process parameters and next-generation strategies","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00476-6","article-title":"Engineering the next generation of cell-based therapeutics","volume":"21","author":"Bashor","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01084-x","article-title":"The therapeutic potential of immunoengineering for systemic autoimmunity","author":"McBride","year":"2024","journal-title":"Nat Rev Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1520063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:18:16Z","timestamp":1744003096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1520063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":163,"alternative-id":["10.3389\/fimmu.2025.1520063"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1520063","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1520063"}}